← All trials
NCT05413668
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jun 10, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Reveal Pharmaceuticals Inc.Lead sponsor
- National Cancer Institute (NCI)Collaborator
- QuotientCollaborator
- QuotientOverall official - principal investigator
- Reveal Pharmaceuticals Inc.Official
- QuotientOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.